Market cap
$521 Mln
Recently Viewed
Clear All$15.00
$0.00 (0.00%)As on 20-Jan-2023 09:30EDT
Market cap
$521 Mln
Revenue (TTM)
$68 Mln
P/E Ratio
--
P/B Ratio
18
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-29 Mln
ROE
-0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-19.7
Debt to Equity
1.3
Book Value
$--
EPS
$-0.9
Face value
--
Shares outstanding
34,763,100
CFO
$-436.02 Mln
EBITDA
$-426.41 Mln
Net Profit
$-465.94 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AVEO Pharmaceuticals (AVEO)
| 0.3 | 0.6 | 1.8 | 302.1 | 33.1 | -12.5 | -15.2 |
|
BSE Sensex*
| -9.2 | 4.5 | -6.1 | -2.9 | 8.2 | 9.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
AVEO Pharmaceuticals (AVEO)
| 218.8 | -18.7 | -7.6 | -61.0 | -42.5 | 416.7 | -57.1 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AVEO Pharmaceuticals (AVEO)
|
15.0 | 521.5 | 68.2 | -29.0 | -35.9 | -88.3 | -- | 18.0 |
| 0.5 | 7.9 | 1.7 | -30.4 | -1,803.2 | -184.5 | -- | 1.0 | |
| 36.0 | 1,218.6 | 0.0 | -61.6 | -- | -33.1 | -- | 7.0 | |
| 11.2 | 299.9 | 19.6 | -176.7 | -839.0 | -- | -- | 2.4 |
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine... kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent's Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts. Read more
CEO, Pres & Director
Mr. Michael P. Bailey
CEO, Pres & Director
Mr. Michael P. Bailey
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of AVEO Pharmaceuticals Inc (AVEO) is $15.00 (NASDAQ) as of 20-Jan-2023 09:30 EDT. AVEO Pharmaceuticals Inc (AVEO) has given a return of 33.14% in the last 3 years.
Since, TTM earnings of AVEO Pharmaceuticals Inc (AVEO) is negative, P/E ratio is not available.
The P/B ratio of AVEO Pharmaceuticals Inc (AVEO) is 17.96 times as on 02-Feb-2023, a 248 premium to its peers’ median range of 5.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-2.90
|
3.37
|
|
2020
|
-3.41
|
3.43
|
|
2019
|
1.00
|
0.63
|
|
2018
|
-3.90
|
-0.76
|
|
2017
|
-0.47
|
-0.75
|
The 52-week high and low of AVEO Pharmaceuticals Inc (AVEO) are Rs -- and Rs -- as of 28-Apr-2026.
AVEO Pharmaceuticals Inc (AVEO) has a market capitalisation of $ 521 Mln as on 02-Feb-2023. As per SEBI classification, it is a Small Cap company.
Before investing in AVEO Pharmaceuticals Inc (AVEO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.